

## DESCRIPTION

<b>Species Reactivity</b>	Human/Mouse
<b>Specificity</b>	Detects human and mouse Caspase-8 in Western blots.
<b>Source</b>	Polyclonal Goat IgG
<b>Purification</b>	Antigen Affinity-purified
<b>Immunogen</b>	<i>E. coli</i> -derived recombinant human Caspase-8 Ser234-Asp496 Accession # AAC50645
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
<b>Western Blot</b>	0.5 µg/mL	See Below
<b>Knockout Validated</b>	Caspase-8 is specifically detected in HeLa human cervical epithelial carcinoma parental cell line but is not detectable in Caspase-8 knockout HeLa cell line.	

## DATA

**Western Blot**

**Detection of Human and Mouse Caspase-8 by Western Blot.** Western blot shows lysates of Jurkat human leukemic T cell line and DA3 mouse myeloma cell line treated with 1 µM staurosporine for the indicated time. PVDF membrane was probed with 0.5 µg/mL Goat Anti-Human/Mouse Caspase-8 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF705) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). Specific bands for Caspase-8 precursor were detected at approximately 60 kDa (as indicated in upper panel) and specific bands for cleaved Caspase-8 were detected at approximately 14-18 kDa (as indicated in lower panel). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 4.

**Knockout Validated**

**Western Blot Shows Human Caspase-8 Specificity by Using Knockout Cell Line.** Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and Caspase-8 knockout HeLa cell line (KO). PVDF membrane was probed with 0.5 µg/mL of Goat Anti-Human/Mouse Caspase-8 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF705) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for Caspase-8 at approximately 58 kDa (as indicated) in the parental HeLa cell line, but is not detectable in knockout HeLa cell line. GAPDH (Catalog # AF5718) is shown as a loading control. This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 0.2 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## BACKGROUND

Caspase-8 (Cysteine-aspartic acid protease 8/Casp8a; also named MCH5, FLICA and MACHd1) is a 28 kDa member of the peptidase C14A family of enzymes (1, 2, 3). It is widely expressed and is considered an initiating caspase for the apoptotic cascade (4). Caspase-8 acts on a wide variety of substrates, including procaspases-3, 4, 6, 7, 9 and 10, c-FLIP<sub>L</sub> and procaspase-8 itself (1, 5, 6). Human procaspase-8a is a 54-56 kDa, 479 amino acid (aa) protein (4, 7, 8, 9). It contains two N-terminal death domains (aa 1-177), followed by a catalytic site that utilizes His317Gly318 plus Cys360. Normally, it is an inactive, cytosolic monomer (1, 10, 11). But following death-domain (DD) containing receptor oligomerization, Caspase-8 is recruited to the death-inducing signaling complex (DISC) that forms around the death domains of the oligomerized receptor (12). FADD/CAP-1 is recruited first, followed by procaspase-8/CAP-4 and, possibly, c-FLIP<sub>L</sub> and procaspase-10 (12). The recruitment, or concentration, of procaspase-8 induces homodimerization. This act alone is sufficient for activation. However, the activity level is modest at best, and appears to be directed towards either itself, or c-FLIP<sub>L</sub>, which is known to form a functional heterodimer with procaspase-8 (5, 11). When directed towards itself, autocleavage occurs first between Asp374Ser375, generating a 43 kDa (p43) N-terminal (aa 1-374) and an 11 kDa C-terminal (aa 375-479) fragment. The C-terminus is further cleaved between Asp384Leu385 to generate a mature p10 subunit (aa 385-479). The p43 subunit is next cleaved twice, once between Asp216Ser217, and again between Asp210Ser211 to generate a 26 kDa DD-containing prodomain (aa 1-210) with an additional 18 kDa mature p18 subunit (aa 217-374) (12). p18 and p10 noncovalently associate to form a 28 kDa heterodimer, which subsequently associates with another p18:p10 heterodimer to form an active, mature Caspase-8 molecule. This leaves the DISC to act on downstream apoptotic procaspases. In the event procaspase-8 comes to the DISC complexed with c-FLIP<sub>L</sub>, c-FLIP<sub>L</sub> will be cleaved by procaspase-8, generating a p43 fragment that is analogous to the Caspase-8 p43 subunit. This fragment, however, appears not to be an intermediate in a proteolytic cascade. Rather, it serves as a functional subunit, interacting with TRAF2 and activating NFκB. This may account for many of the nonapoptotic activities associated with Caspase-8 (5, 6, 13). Mature human and mouse Caspase-8a heterodimers are 73% aa identical (14).

## References:

1. Chowdhury, I. *et al.* (2008) *Comp. Biochem. Physiol. B* **151**:10.
2. Boatright, K.M. & G.S. Salvesen (2003) *Curr. Opin. Cell Biol.* **15**:725.
3. Launay, S. *et al.* (2005) *Oncogene* **24**:5137.
4. Srinivasula, S.M. *et al.* (1996) *Proc. Natl. Acad. Sci. USA* **93**:14486.
5. Hughes, M.A. *et al.* (2009) *Mol. Cell* **35**:265.
6. Lamkanfi, M. *et al.* (2007) *Cell Death Differ.* **14**:44.
7. Fernandes-Alnemri, T. *et al.* (1996) *Proc. Natl. Acad. Sci. USA* **93**:7464.
8. Boldin, M.P. *et al.* (1996) *Cell* **85**:803.
9. Muzio, M. *et al.* (1996) *Cell* **85**:817.
10. Donepudi, M. *et al.* (2003) *Mol. Cell* **11**:543.
11. Boatright, K.M. *et al.* (2003) *Mol. Cell* **11**:529.
12. Golks, A. *et al.* (2006) *Cell Death Differ.* **13**:489.
13. Scaffidi, C. *et al.* (1997) *J. Biol. Chem.* **272**:26953.
14. Sakamaki, K. *et al.* (1998) *Eur. J. Biochem.* **253**:399.